JP6886578B1 - 化合物又はその塩、がん治療薬、光増感剤、及び蛍光プローブ組成物 - Google Patents
化合物又はその塩、がん治療薬、光増感剤、及び蛍光プローブ組成物 Download PDFInfo
- Publication number
- JP6886578B1 JP6886578B1 JP2020146971A JP2020146971A JP6886578B1 JP 6886578 B1 JP6886578 B1 JP 6886578B1 JP 2020146971 A JP2020146971 A JP 2020146971A JP 2020146971 A JP2020146971 A JP 2020146971A JP 6886578 B1 JP6886578 B1 JP 6886578B1
- Authority
- JP
- Japan
- Prior art keywords
- compound
- structural formula
- group
- formula
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 151
- 239000000203 mixture Substances 0.000 title claims abstract description 26
- 150000003839 salts Chemical class 0.000 title claims abstract description 22
- 239000003504 photosensitizing agent Substances 0.000 title claims abstract description 17
- 239000007850 fluorescent dye Substances 0.000 title claims abstract description 10
- 239000012830 cancer therapeutic Substances 0.000 title claims abstract description 7
- 229940124597 therapeutic agent Drugs 0.000 title claims abstract description 7
- 125000001424 substituent group Chemical group 0.000 claims description 22
- 150000004032 porphyrins Chemical group 0.000 claims description 12
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 11
- 125000005647 linker group Chemical group 0.000 claims description 6
- 238000002428 photodynamic therapy Methods 0.000 claims description 6
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 125000002947 alkylene group Chemical group 0.000 claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 125000004665 trialkylsilyl group Chemical group 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 abstract description 24
- -1 porphyrin compound Chemical class 0.000 abstract description 15
- 159000000000 sodium salts Chemical class 0.000 abstract description 7
- 238000010586 diagram Methods 0.000 abstract description 3
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 abstract description 2
- 125000004185 ester group Chemical group 0.000 abstract 1
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical group CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 abstract 1
- 238000004949 mass spectrometry Methods 0.000 description 41
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 36
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
- 238000005160 1H NMR spectroscopy Methods 0.000 description 28
- 239000000243 solution Substances 0.000 description 23
- 239000007795 chemical reaction product Substances 0.000 description 22
- 238000005259 measurement Methods 0.000 description 21
- 238000001228 spectrum Methods 0.000 description 17
- 201000011510 cancer Diseases 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 16
- 239000011734 sodium Substances 0.000 description 16
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 15
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 14
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 14
- 239000011259 mixed solution Substances 0.000 description 13
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 13
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- 235000002597 Solanum melongena Nutrition 0.000 description 12
- 238000010898 silica gel chromatography Methods 0.000 description 12
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 11
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical group [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 10
- 125000001931 aliphatic group Chemical group 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 description 8
- 239000007983 Tris buffer Substances 0.000 description 7
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 7
- 235000019341 magnesium sulphate Nutrition 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 239000012074 organic phase Substances 0.000 description 7
- 229920006395 saturated elastomer Polymers 0.000 description 7
- 235000017557 sodium bicarbonate Nutrition 0.000 description 7
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 7
- 229910052717 sulfur Inorganic materials 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 6
- 239000011593 sulfur Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 229910052786 argon Inorganic materials 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 238000000862 absorption spectrum Methods 0.000 description 4
- 125000003368 amide group Chemical group 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 238000002189 fluorescence spectrum Methods 0.000 description 4
- 125000000623 heterocyclic group Chemical group 0.000 description 4
- 150000002430 hydrocarbons Chemical group 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 238000006862 quantum yield reaction Methods 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- UIKLGFJFFRWBIV-UHFFFAOYSA-N C[Si](C)(C)c1cccc(c1)C(N)=O Chemical compound C[Si](C)(C)c1cccc(c1)C(N)=O UIKLGFJFFRWBIV-UHFFFAOYSA-N 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical group ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 2
- HZNVUJQVZSTENZ-UHFFFAOYSA-N 2,3-dichloro-5,6-dicyano-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(C#N)=C(C#N)C1=O HZNVUJQVZSTENZ-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N Glutamine Chemical compound OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 2
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 2
- 150000001540 azides Chemical class 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- SURLGNKAQXKNSP-DBLYXWCISA-N chlorin Chemical compound C\1=C/2\N/C(=C\C3=N/C(=C\C=4NC(/C=C\5/C=CC/1=N/5)=CC=4)/C=C3)/CC\2 SURLGNKAQXKNSP-DBLYXWCISA-N 0.000 description 2
- GGSUCNLOZRCGPQ-UHFFFAOYSA-N diethylaniline Chemical compound CCN(CC)C1=CC=CC=C1 GGSUCNLOZRCGPQ-UHFFFAOYSA-N 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 230000001678 irradiating effect Effects 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 229910015900 BF3 Inorganic materials 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- AZMSIWIKAZBRMD-UHFFFAOYSA-N C(=O)(O)C=1C=C(C=O)C=C(C1)[Si](C)(C)C Chemical compound C(=O)(O)C=1C=C(C=O)C=C(C1)[Si](C)(C)C AZMSIWIKAZBRMD-UHFFFAOYSA-N 0.000 description 1
- ADTFUQGWARDQHO-CTUDHRKMSA-N CC(C([C@H]([C@H]([C@@H]([C@H]1OCC2=CC=CC=C2)OCC2=CC=CC=C2)OCC2=CC=CC=C2)O[C@@H]1OCCCS(C1=CC=C(C)C=C1)(=O)=O)O)=S Chemical compound CC(C([C@H]([C@H]([C@@H]([C@H]1OCC2=CC=CC=C2)OCC2=CC=CC=C2)OCC2=CC=CC=C2)O[C@@H]1OCCCS(C1=CC=C(C)C=C1)(=O)=O)O)=S ADTFUQGWARDQHO-CTUDHRKMSA-N 0.000 description 1
- WDBPFMJUOZARDX-MANRWTMFSA-N CC(C=C1)=CC=C1S(CCCO[C@H]([C@@H]([C@H]1OCC2=CC=CC=C2)OCC2=CC=CC=C2)O[C@H](CO)[C@H]1OCC1=CC=CC=C1)(=O)=O Chemical compound CC(C=C1)=CC=C1S(CCCO[C@H]([C@@H]([C@H]1OCC2=CC=CC=C2)OCC2=CC=CC=C2)O[C@H](CO)[C@H]1OCC1=CC=CC=C1)(=O)=O WDBPFMJUOZARDX-MANRWTMFSA-N 0.000 description 1
- RLMZABDIRNGOKT-UHFFFAOYSA-N COC(C1=CC([Si](C)(C)C)=CC(C2=C(C=C(C=C3)N=C3C=C(C=C3)NC3=CC(C=C3)=NC3=C3)NC3=C2)=C1)=O Chemical compound COC(C1=CC([Si](C)(C)C)=CC(C2=C(C=C(C=C3)N=C3C=C(C=C3)NC3=CC(C=C3)=NC3=C3)NC3=C2)=C1)=O RLMZABDIRNGOKT-UHFFFAOYSA-N 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 125000005336 allyloxy group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 208000026900 bile duct neoplasm Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- PBHVCRIXMXQXPD-UHFFFAOYSA-N chembl2369102 Chemical compound C1=CC(S(=O)(=O)O)=CC=C1C(C1=CC=C(N1)C(C=1C=CC(=CC=1)S(O)(=O)=O)=C1C=CC(=N1)C(C=1C=CC(=CC=1)S(O)(=O)=O)=C1C=CC(N1)=C1C=2C=CC(=CC=2)S(O)(=O)=O)=C2N=C1C=C2 PBHVCRIXMXQXPD-UHFFFAOYSA-N 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000002933 cyclohexyloxy group Chemical group C1(CCCCC1)O* 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000005281 excited state Effects 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 230000005283 ground state Effects 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- BTXNYTINYBABQR-UHFFFAOYSA-N hypericin Chemical class C12=C(O)C=C(O)C(C(C=3C(O)=CC(C)=C4C=33)=O)=C2C3=C2C3=C4C(C)=CC(O)=C3C(=O)C3=C(O)C=C(O)C1=C32 BTXNYTINYBABQR-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000025036 lymphosarcoma Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000013307 optical fiber Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 125000004115 pentoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000001443 photoexcitation Effects 0.000 description 1
- IEQIEDJGQAUEQZ-UHFFFAOYSA-N phthalocyanine Chemical class N1C(N=C2C3=CC=CC=C3C(N=C3C4=CC=CC=C4C(=N4)N3)=N2)=C(C=CC=C2)C2=C1N=C1C2=CC=CC=C2C4=N1 IEQIEDJGQAUEQZ-UHFFFAOYSA-N 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 238000001269 time-of-flight mass spectrometry Methods 0.000 description 1
- 125000005389 trialkylsiloxy group Chemical group 0.000 description 1
- 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H23/00—Compounds containing boron, silicon, or a metal, e.g. chelates, vitamin B12
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
- C09B47/00—Porphines; Azaporphines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/062—Photodynamic therapy, i.e. excitation of an agent
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
R 1 、R 2 、R 4 、R 5 、R 7 、R 8 、R 10 、及びR 11 は水素原子であり、
R 3 、R 6 、及びR 9 は下記式(iii)の置換基であり、
R13はスルホ基であり、
前記式(i)及び(ii)において、Ra、Rb、及びRcはそれぞれ独立してC 1 〜C 6 のアルキル基から選ばれる置換基であり、
前記式(iii)において、Rdは水素原子又はC1〜C 6 のアルキル基であり、Rxは前記式(i)又は(ii)に示される置換基である。
以下、構造式(IIa)で表される化合物(構造式(10)としても示される)のナトリウム塩合成方法の一例について説明を行う。本実施例では、3−トリメチルシリル−1−ベンゼンカルボキシアミド,N−[3−n−プロピル−α−D−キノボピラノシド]−5−[10,15,20−トリス(3−カルボネート−5−トリメチルシリルフェニル)ポルフィリン] 4ナトリウム塩(構造式(11))が、以下の経路A〜Gにしたがって合成された。
MS:測定値m/z 1120.19[M+H]、計算値 1121.41[M+H]
δ=8.95−8.93 (d,1H),8.88−8.85 (m,3H),8.82 (s,8H),8.67 (s,1H),8.61 (s,3H),8.59 (s,1H),8.55−8.53 (m,3H),4.00 (s,9H),0.45 (s,36H),−2.75 (s,2H)ppm
MS:測定値m/z 743.02[M+Na]、計算値 732.24[M+Na]
δ=7.79−7.76 (d,2H),7.38−7.28 (m,17H),4.96−4.88 (q,2H),4.79−4.71 (q,2H),4.64−4.63 (t,2H),4.61−4.60 (d,1H),4.22−4.08 (m,2H),3.88−3.84 (t,1H),3.75−3.66 (m,2H),3.51−3.39 (m,3H),3.32−3.28 (t,1H),3.04−2.99 (q,1H),2.39 (s,3H),2.35 (s,3H),2.00−1.94 (m,2H),1.59 (s,2H)ppm
MS:測定値m/z 564.13[M−N2+H]、計算値 564.24[M−N2+H]、計算式 C32H37N3O6S
δ=7.41−7.29 (m,15H),5.01−4.99 (d,1H),4.93−4.90 (d,1H),4.84−4.77 (q,2H),4.67−4.63 (m,3H),3.99−3.94 (t,1H),3.79−3.73 (m,2H),3.55−3.51 (q,1H),3.47−3.37 (m,4H),3.35−3.31 (t,1H),3.07−3.01 (q,1H),2.35 (s,3H),1.95−1.87 (m,2H),1.27 (s,1H)ppm
MS:測定値m/z 598.84[M−Na+H2]、計算値 598.21[M−Na+H2]、計算式 C30H34N3NaO8S
δ=7.30−7.19 (m,15H),4.93−4.90 (d,1H),4.80−4.77 (d,2H),4.69−4.53 (m,4H),4.18−4.13 (t,1H),3.94−3.86 (m,2H),3.63−3.43 (m,6H),3.41−3.25 (m,4H),3.22−3.17 (t,1H),3.11−3.05 (q,1H),1.82−1.74 (m,2H),1.25−1.22 (m,1H)ppm
MS:測定値m/z 302.15[M−Na+H2]、計算値 302.08[M−Na+H2] 計算値 C9H19NNaO8S
δ=4.80−4.79 (d,1H),3.97−3.86 (m,2H),3.62−3.54,(q,1H),3.52−3.47 (m,2H),3.31−3.26 (d,1H),3.20−3.13 (t,1H),3.08−3.04 (t,2H),3.01−2.93 (q,1H),1.97−1.88 (m,2H)ppm
MS:測定値m/z 1404.22[M−Na+H2]、計算値 1404.48[M−Na+H2]、計算式 C72H85N5NaO15SSi4
δ=8.99−8.48 (br,20H),4.74−4.73 (m,1H),4.15−4.05 (m,2H),3.97 (s,9H),3.78−3.70 (m,1H),3.64−3.59 (t,2H),3.55−3.49 (m,2H),3.35−3.32 (m,1H),3.03−2.93 (m,2H),2.88−2.82 (q,1H),2.03−1.96 (m,2H),0.46−0.42 (m,36H)ppm
MS:測定値m/z 1363.31[M−Na4+H5]、計算値 1362.44[M−Na4+H5]、計算式 C69H75N5Na4O15SSi4
δ =8.96−8.49 (br,20H),4.72−4.70 (m,1H),4.13−4.03 (m,2H),3.75−3.66 (m,1H),3.63−3.55 (m,1H),3.52−3.42 (m,2H),3.34−3.30 (m,1H),2.93−2.87 (q,1H),2.85−2.80 (m,1H),1.98 (br,2H),0.45−0.41 (m,36H)ppm
また、以下、本発明に係る光増感剤の一態様である3−トリメチルシリル−1−ベンゼンカルボキシアミド,N−[3−n−プロピル−α−D−グルコピラノシド]−5−[10,15,20−トリス(3−カルボネート−5−トリメチルシリルフェニル)ポルフィリン] 3ナトリウム塩(以下の構造式(17))の合成方法の一例について説明を行う。本実施形態においては、以下の経路H〜Lにしたがって構造式(17)に示される化合物が合成された。
MS:測定値m/z 661.14[M+Na]、計算値 661.24[M+Na]
δ=7.81−7.78 (m,2H),7.54−7.52 (m,2H),7.42−7.25 (m,15H),5.67 (s,1H),4.94 (d,1H),4.88−4.78 (q,2H),4.76−4.68 (q,2H),4.24−4.17 (m,3H),4.08−4.02 (q,1H),3.86−3.80 (m,2H),3.78−3.70 (m,2H),3.68−3.63 (m,1H),3.60−3.56 (q,1H),3.53−3.47 (m,1H),2.81 (s,1H),2.37 (s,3H),2.00−1.97 (t,1H),1.96−1.94 (d,1H)ppm
MS:測定値m/z 504.27[M−N2+H]、計算値 503.23[M−N2+H]
δ=7.52−7.49 (m,2H),7.43−7.24 (m,13H),5.67 (s,1H),5.00−4.99 (d,1H),4.91−4.81 (q,2H),4.81−4.72 (q,2H),4.23−4.20 (q,1H),3.97−3.92 (t,1H),3.89−3.84 (m,1H),3.82−3.76 (m,2H),3.73−3.65 (q,1H),3.63−3.60 (q,1H),3.57−3.50 (m,3H),2.80 (s,1H),1.95−1.88 (m,2H)ppm
MS:測定値m/z 238.30[M+H]、計算値 238.12[M+H]
δ=4.86−4.85 (d,1H),3.86−3.80 (m,1H),3.77 (d,1H),3.70−3.64 (m,1H),3.61−3.55 (m,2H),3.55−3.49 (m,2H),3.36−3.31 (t,1H),3.14−3.02 (m,2H),1.97−1.90 (m,2H)ppm
MS:測定値m/z 1341.54[M+H]、計算値 1340.52[M+H]
δ=8.86−8.45 (br,20H),4.72−4.71 (m,1H),3.92 (s,9H),3.81−3.79 (m,1H),3.73−3.70 (d,1H),3.58−3.54 (m,6H),3.32−3.31 (m,1H),3.20−3.15 (m,1H),2.01−1.93 (m,2H),0.43−0.38 (m,36H)ppm
MS:測定値m/z 1298.68[M−Na3+H4]、計算値 1298.48[M−Na3+H4]、計算式 C69H76N5Na3O13Si4
δ =8.84−8.41 (br,20H),4.74−4.71 (q,1H),3.85−3.77 (m,1H),3.74−3.67 (m,1H),3.60−3.48 (m,6H),3.32−3.30 (m,1H),3.20−3.16 (t,1H),1.94 (br,2.04),0.45−0.42 (m,36H)ppm
構造式(10)及び(11)の化合物は、ポルフィリン類縁体である下記の構造式(III)に示される化合物に含硫糖鎖を導入した化合物である。構造式(III)の化合物は、非特許文献2−4に記載されるように、優れた一重項酸素の光学的性質を有している。ここで、含硫糖鎖を結合することによっても、構造式(III)で示されるポルフィリン化合物の優れた光化学的性質が維持されることを確認した。図1は、構造式(IIa)、(IId)、及び(III)のそれぞれに示される化合物の吸収スペクトル及び蛍光スペクトルをまとめた図である。なお、構造式(IIa)及び(IId)は、それぞれ構造式(III)のフェニル基に含硫糖鎖及び糖鎖を結合させた化合物である。
また、構造式(III)の化合物に含硫糖鎖を結合することにより、腫瘍への集積性が向上する。以下、そのような集積性の向上について、構造式(IIa)及び(III)の化合物を用いた、がん細胞に対する取り込み効率の評価を行った。
Claims (9)
- 下記式(I)によって表される化合物又はその塩。
前記式(I)中、Aは−X−NHCO−で表される、XがC 1 〜C 6 のアルキレン基である連結基であり、
R 1 、R 2 、R 4 、R 5 、R 7 、R 8 、R 10 、及びR 11 は水素原子であり、
R 3 、R 6 、及びR 9 は下記式(iii)の置換基であり、
R12は前記式(i)又は(ii)から選ばれる置換基であり、
R13はスルホ基であり、
前記式(i)及び(ii)において、Ra、Rb、及びRcはそれぞれ独立してC 1 〜C 6 のアルキル基から選ばれる置換基であり、
前記式(iii)において、Rdは水素原子又はC1〜C 6 のアルキル基であり、Rxは前記式(i)又は(ii)に示される置換基である。 - 前記式(i)及び(ii)において、Ra、Rb、及びRcはメチル基であることを特徴とする、請求項1に記載の化合物又はその塩。
- 前記式(iii)において、Rdはメチル基であることを特徴とする、請求項1又は2に記載の化合物又はその塩。
- R12はトリアルキルシリル基であることを特徴とする、請求項1乃至3の何れか一項に記載の化合物又はその塩。
- 置換基R12及びAがそれぞれポルフィリン環の結合部位に対してメタ位に結合していることを特徴とする、請求項1乃至4の何れか一項に記載の化合物又はその塩。
- 請求項1乃至6の何れか一項に記載の化合物又はその塩を含有するがん治療薬。
- 請求項1乃至6の何れか一項に記載の化合物又はその塩を含有する、光線力学療法用の光増感剤。
- 請求項1乃至6の何れか一項に記載の化合物又はその塩を含有する蛍光プローブ組成物。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020146971A JP6886578B1 (ja) | 2020-09-01 | 2020-09-01 | 化合物又はその塩、がん治療薬、光増感剤、及び蛍光プローブ組成物 |
EP21193612.5A EP3960750B1 (en) | 2020-09-01 | 2021-08-27 | Photosensitizing agent, and fluorescent probe composition |
US17/462,279 US11643430B2 (en) | 2020-09-01 | 2021-08-31 | Porphyrin compound or salt thereof, cancer therapeutic agent, photosensitizer, and fluorescent probe |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020146971A JP6886578B1 (ja) | 2020-09-01 | 2020-09-01 | 化合物又はその塩、がん治療薬、光増感剤、及び蛍光プローブ組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP6886578B1 true JP6886578B1 (ja) | 2021-06-16 |
JP2022041643A JP2022041643A (ja) | 2022-03-11 |
Family
ID=76310227
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020146971A Active JP6886578B1 (ja) | 2020-09-01 | 2020-09-01 | 化合物又はその塩、がん治療薬、光増感剤、及び蛍光プローブ組成物 |
Country Status (3)
Country | Link |
---|---|
US (1) | US11643430B2 (ja) |
EP (1) | EP3960750B1 (ja) |
JP (1) | JP6886578B1 (ja) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4253453A (en) | 1979-10-19 | 1981-03-03 | Airco, Inc. | Selector valve for anesthesia machine |
US4935498A (en) | 1989-03-06 | 1990-06-19 | Board Of Regents, The University Of Texas System | Expanded porphyrins: large porphyrin-like tripyrroledimethine-derived macrocycles |
DE69922216T2 (de) | 1998-08-28 | 2005-12-01 | Destiny Pharma Ltd. | Porphyrin derivate, ihre verwendung in der photodynamischen therapie und diese enthaltende medizinische geräte |
EP1279676A1 (en) * | 2001-07-19 | 2003-01-29 | Institut Curie | Porphyrin derivatives for photodynamic therapy |
JP5843113B2 (ja) | 2010-09-02 | 2016-01-13 | 国立大学法人群馬大学 | 含ケイ素置換基を導入した化合物、並びにそれを含む一重項酸素発生剤及び癌治療薬 |
-
2020
- 2020-09-01 JP JP2020146971A patent/JP6886578B1/ja active Active
-
2021
- 2021-08-27 EP EP21193612.5A patent/EP3960750B1/en active Active
- 2021-08-31 US US17/462,279 patent/US11643430B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP3960750B1 (en) | 2023-05-24 |
EP3960750A1 (en) | 2022-03-02 |
JP2022041643A (ja) | 2022-03-11 |
US11643430B2 (en) | 2023-05-09 |
US20220064203A1 (en) | 2022-03-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2758904C (en) | Novel compounds of reverse-turn mimetics, method for manufacturing the same and use thereof | |
Molenaar et al. | New insights in the cellular processing of platinum antitumor compounds, using fluorophore-labeled platinum complexes and digital fluorescence microscopy | |
KR101897307B1 (ko) | 모르폴리닐 안트라사이클린 유도체의 제조 방법 | |
CN111315415A (zh) | 可编程的聚合药物 | |
CN111565757A (zh) | 包含生物活性化合物的磷酸烷基聚合物 | |
EA024627B1 (ru) | Производные криптофицина и его конъюгаты, их получение и применение в терапии | |
US11988667B2 (en) | Fluorescent compound and fluorescent labeled biological substance using the same | |
FR2978149A1 (fr) | Nouveaux agents complexants et complexes de lanthanide correspondant, et leur utilisation comme marqueurs luminescents | |
WO2014055505A1 (en) | Bodipy dyes for biological imaging | |
Treekoon et al. | Glucose conjugated aza-BODIPY for enhanced photodynamic cancer therapy | |
EP4001285A1 (en) | Near-infrared (nir) absorbing photosensitizers | |
JP6886578B1 (ja) | 化合物又はその塩、がん治療薬、光増感剤、及び蛍光プローブ組成物 | |
Suvorov et al. | Synthesis of PSMA-targeted 131-and 152-substituted chlorin e6 derivatives and their biological properties | |
AU2008278337B2 (en) | Novel sulfonated sugar compound and use thereof as medicine | |
Staegemann et al. | A toolset of functionalized porphyrins with different linker strategies for application in bioconjugation | |
WO2020260424A1 (en) | Ruthenium (ii) complexes and conjugates thereof for use as photosensitizer agent in photodynamic therapy | |
CN114349738A (zh) | 一类靶向降解cdk2的小分子缀合物及其应用 | |
KR20110066927A (ko) | 생체 내 영상화제로서 사용하기 위한 이사틴 유도체 | |
Rousselle et al. | Development of a novel highly anti-proliferative family of gold complexes: Au (i)-phosphonium-phosphines | |
EP3684781A1 (en) | Bioreductively-activated compounds, their prodrugs, radiopharmaceuticals, the compositions, and their applications in multimodal theranostic management of hypoxia diseases including cancer | |
KR20220103984A (ko) | Mcl-1 억제제로서의 거대환식 인돌 유도체 | |
EP4144731A1 (en) | Compounds containing benzosultam | |
JP2022542288A (ja) | 再構成骨髄枯渇宿主の生存を高めるためのe-セレクチンアンタゴニストの使用 | |
Iakovides et al. | Syntheses of oxygen analogues of sulfhemes-A and-C | |
CN110590877B (zh) | 连接子,载药连接子、细胞穿透肽偶联药物、抗体偶联药物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200902 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200916 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200925 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20201202 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20201202 |
|
A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20201218 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210129 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210324 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210402 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210409 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6886578 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
R371 | Transfer withdrawn |
Free format text: JAPANESE INTERMEDIATE CODE: R371 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |